Over the past year, OpenAI has dominated headlines with ChatGPT and breakthroughs in generative AI. Now, the company has quietly entered the laboratory, and its first biological research initiative signals a profound shift in longevity science.
In collaboration with Retro Biosciences, OpenAI has developed GPT-4b micro, a specialized AI model that surpasses human capabilities in stem cell research. This venture into biological engineering marks a decisive step beyond language processing, and the results are remarkable. Early testing shows that the model achieves cellular reprogramming with 50 times greater efficiency than conventional methods, rewriting established rules of cellular biology.
